share_log

HC Wainwright & Co. Initiates Coverage On Cadrenal Therapeutics With Buy Rating, Announces Price Target of $3

Benzinga ·  Nov 20, 2023 07:05

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy rating and announces Price Target of $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment